RxSight Q2 adjusted loss beats estimates; withdraws 2026 guidance

RxSight

05/08/2026 22:07

Overview
US ophthalmic device maker's Q2 revenue was $33.7 mln, including $6.5 mln from Alcon collaboration
Q2 product sales fell 19% yr/yr due to heightened competition and weak consumer sentiment
Adjusted loss per share for Q2 beat analyst expectations

Outlook
Company withdrew 2026 guidance and will resume formal guidance in early 2027

Result Drivers
COMPETITIVE PRESSURE - Co said heightened competitive trialing contributed to 19% yr/yr decline in Q2 product sales
WEAK CONSUMER SENTIMENT - Co said continued pressure on consumer sentiment contributed to lower Q2 product sales
ALCON COLLABORATION - $6.5 mln in collaboration revenue from Alcon favorably impacted Q2 gross margin

Company press release: ID:nGNX9sj0HQ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
Beat
$0.11
$0.33 (10 Analysts)
Q2 Loss Per Share
 
$0.29
 
Q2 Adjusted Net Loss
 
$4.63 mln
 
Q2 Operating Expenses
 
$39.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for RxSight, Inc. is $8.00, about 28% above its August 4 closing price of $6.25

Reuters Recommended Reads
Aug 3 - Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spending
Aug 5 - EyePoint Pharmaceuticals Q2 revenue drops on lower license income
Aug 5 - InMode Q2 revenue beats estimates on steady U.S. demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)